top of page
Executive Spotlights

Teva names Richard Francis as CEO

Tel Aviv, Israel, November 21, 2023 (Reuters) -- Teva Pharmaceutical (TEVA.TA) has named Richard Francis, former executive at Novartis (NOVN.S) and Biogen (BIIB.O), as the successor to CEO Kare Schultz, set to retire later this year. Currently leading gene therapy firm Purespring Therapeutics and biopharma company Forcefield Therapeutics, Francis will assume the position of Teva's president, starting Jan. 1, 2023.


Read full article here.

Recent Posts

See All
Life Science Headlines
bottom of page